{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluid+Management&page=25", "query": { "intervention": "Fluid Management", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 686, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluid+Management&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluid+Management&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T17:27:26.077Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04444245", "title": "Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Failure", "Perimenopausal Disorder", "Hormone Disturbance" ], "interventions": [ { "name": "lipoaspiration harvest tSVF", "type": "PROCEDURE" }, { "name": "Platelet Rich Plasma", "type": "PROCEDURE" }, { "name": "Endovaginal Ultrasound", "type": "PROCEDURE" }, { "name": "Cellular Isolation cSVF", "type": "DEVICE" }, { "name": "Normal Saline (NS) .9% 10 mL Injection", "type": "DRUG" }, { "name": "emulsification tSVF", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DEVICE", "DRUG" ], "sponsor": "Black Tie Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "35 Years to 60 Years · Female only" }, "enrollment_count": 100, "start_date": "2022-07-15", "completion_date": "2025-08-15", "has_results": false, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 1, "location_summary": "Colchester, Vermont", "locations": [ { "city": "Colchester", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT04444245" }, { "nct_id": "NCT05051722", "title": "Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Endometrial Cancer", "Cervical Cancer", "Atypical Endometrial Hyperplasia", "Cervical Dysplasia", "Adnexal Mass", "Ovarian Cancer" ], "interventions": [ { "name": "Vaginal Fluid Collection", "type": "DIAGNOSTIC_TEST" }, { "name": "Blood Collection", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3110, "start_date": "2021-08-03", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05051722" }, { "nct_id": "NCT03556592", "title": "Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-13", "completion_date": "2020-06-20", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556592" }, { "nct_id": "NCT01982539", "title": "Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Zipsor®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Depomed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 25, "start_date": "2013-11", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 2, "location_summary": "Sheffield, Alabama • Stanford, California", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01982539" }, { "nct_id": "NCT06807437", "title": "Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Carcinoma", "Pancreatic Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Distal Pancreatectomy", "type": "PROCEDURE" }, { "name": "Lanreotide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2025-05-09", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 118, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06807437" }, { "nct_id": "NCT02133937", "title": "A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "gantenerumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2014-04", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02133937" }, { "nct_id": "NCT04371445", "title": "Dextenza in the Post-op Management of Vitreoretinal Surgeries", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Vitreoretinal Surgery", "Ocular Inflammation", "Post-operative Pain", "Post-Operative Inflammation" ], "interventions": [ { "name": "Dexamethasone Ophthalmic Insert", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% Oph Susp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-06-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04371445" }, { "nct_id": "NCT06451120", "title": "Platelet Rich Plasma Injections In Young And Old Human Subjects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis", "Articular Cartilage", "Musculoskeletal Disorders" ], "interventions": [ { "name": "Platelet-Rich Plasma (PRP) Injections", "type": "DRUG" }, { "name": "Centrifuge", "type": "DEVICE" }, { "name": "Control saline injection", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2024-06-01", "completion_date": "2027-02-16", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451120" }, { "nct_id": "NCT01175213", "title": "Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immunodeficiency Diseases (PID)" ], "interventions": [ { "name": "SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)", "type": "BIOLOGICAL" }, { "name": "SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)", "type": "BIOLOGICAL" }, { "name": "IV treatment with IGSC, 10%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 66, "start_date": "2010-07-28", "completion_date": "2013-08-06", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 11, "location_summary": "Cypress, California • Irvine, California • Los Angeles, California + 8 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175213" }, { "nct_id": "NCT03187080", "title": "Enhanced Recovery Strategies in Elective Breast Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain, Acute", "Nausea", "Vomiting, Postoperative", "Opioid Use", "Satisfaction" ], "interventions": [ { "name": "Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline", "type": "PROCEDURE" }, { "name": "Enhanced recovery after breast surgery (ERABS) strategies", "type": "OTHER" }, { "name": "Sham paravertebral block using saline", "type": "PROCEDURE" }, { "name": "Paravertebral block using local anesthetic", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 113, "start_date": "2017-10-19", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2024-08-23", "last_synced_at": "2026-10-23T17:27:26.077Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03187080" } ] }